ArticleEuropean journal of nuclear medicine and molecular imaging2026
Dual‑targeted radioligand therapy with [
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeTo evaluate the feasibility, safety and preliminary efficacy of dual-targeted radioligand therapy combining [
methodsThis prospective, single-center, single-arm study enrolled 30 patients with bone metastases from NENs to receive combined [
resultsA total of 95 treatment cycles were administered. The overall bone pain relief rate was 95.9%, with complete pain resolution in 41.7% of patients. Among 24 evaluable patients, the objective response rates (ORR) were 16.7% by RECIST 1.1, 50% by SSTR-PERCIST, and 29.2% by MDAC. The corresponding disease control rates (DCR) were 79.2%, 79.2%, and 87.5%, respectively. Subgroup analyses revealed comparable ORRs and DCRs between GEP-NENs (n = 14) and non-GEP-NENs (n = 10) across all three criteria. Semi-Quantitative PET/CT parameters, including STV, SUVmax, SUVmean, TLS, TBR, SULpeak, SLD and TBV decreased significantly after treatment (all P < 0.05). Absorbed doses to critical organs remained within safe thresholds. No grade ≥ 4 AEs occurred. No significant difference in PFS was observed between the two subgroups (log-rank P = 0.828).
conclusionOur findings suggest that dual-targeted radioligand therapy with [
Indexed as
Identifiers
42572057What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.